{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:09:40Z","timestamp":1787724580363,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment landscape for multiple sclerosis (MS) is quickly evolving. Understanding real-world treatment patterns of patients is necessary to identifying potential gaps in care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with incident MS were identified from a large national claims database during 1\/1\/2014\u20136\/30\/2019. Patients had \u22652 diagnoses for MS or an inpatient hospitalization with a primary diagnosis of MS. Patients were required to have enrollment in the database \u22651\u2009year prior to and\u2009\u2265\u20091\u2009year following their first MS diagnosis. Treatment sequences were captured for all available disease modifying therapies (DMTs) during all available follow-up. Presence of comorbid conditions were captured during the one year prior to and following (and including) the index date; absolute change in prevalence from the pre- to post-index periods was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 5691 patients with incident MS. Common comorbidities included physical symptoms (e.g., pain, weakness, fatigue), mental health conditions (anxiety, depression), and cardiovascular\/metabolic conditions (hypertension, hyperlipidemia, diabetes, obesity). Just 1994 (35.0%) of patients received a DMT at any time during follow-up. Of those receiving a DMT, 28.2% went on to receive a second line of therapy, 5.8% received a third, and just 0.9% went on to a fourth line. Use of more than one DMT concomitantly occurred in just 1.8% of all treated patients. Glatiramer and dimethyl fumarate were by far the most common first-line treatments received accounting for nearly 62% of patients receiving a DMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Approximately two-thirds of patients newly diagnosed with MS did not receive a DMT and the disease is accompanied by a significant comorbid burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-020-01882-2","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T05:25:35Z","timestamp":1597123535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-3925","authenticated-orcid":false,"given":"David M.","family":"Kern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Soledad","family":"Cepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"issue":"9313","key":"1882_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet (London, England). 2002;359(9313):1221\u201331.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"1882_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/s-0036-1579693","volume":"36","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Munger KL. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin Neurol. 2016;36(2):103\u201314.","journal-title":"Semin Neurol"},{"key":"1882_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-12-802973-2.00011-2","volume":"138","author":"DS Goodin","year":"2016","unstructured":"Goodin DS. The epidemiology of multiple sclerosis: insights to a causal cascade. Handb Clin Neurol. 2016;138:173\u2013206.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"1882_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","volume":"172","author":"E Leray","year":"2016","unstructured":"Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172(1):3\u201313.","journal-title":"Rev Neurol"},{"issue":"4","key":"1882_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s13167-019-00192-z","volume":"10","author":"S Gehr","year":"2019","unstructured":"Gehr S, Kaiser T, Kreutz R, Ludwig WD, Paul F. Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. EPMA J. 2019;10(4):425\u201336.","journal-title":"EPMA J"},{"issue":"3","key":"1882_CR6","first-page":"761","volume":"22","author":"MS Freedman","year":"2016","unstructured":"Freedman MS, Rush CA. Severe, highly active, or aggressive multiple sclerosis. Continuum (Minneapolis, Minn). 2016;22(3):761\u201384.","journal-title":"Continuum (Minneapolis, Minn)"},{"issue":"6 Suppl","key":"1882_CR7","first-page":"s159","volume":"22","author":"FM Hart","year":"2016","unstructured":"Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016;22(6 Suppl):s159\u201370.","journal-title":"Am J Manag Care"},{"key":"1882_CR8","unstructured":"National Multiple Sclerosis Society. Disease-modifying therapies for MS 2020 [Last Accessed: May 18, 2020]. Available from: http:\/\/www.nationalmssociety.org\/nationalmssociety\/media\/msnationalfiles\/brochures\/brochure-the-ms-disease-modifying-medications.pdf."},{"issue":"1","key":"1882_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40120-018-0123-y","volume":"8","author":"M Sanchirico","year":"2019","unstructured":"Sanchirico M, Caldwell-Tarr A, Mudumby P, Hashemi L, Dufour R. Treatment patterns, healthcare resource utilization, and costs among Medicare patients with multiple sclerosis in relation to disease-modifying therapy and corticosteroid treatment. Neurol Therapy. 2019;8(1):121\u201333.","journal-title":"Neurol Therapy"},{"issue":"3","key":"1882_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1474-4422(10)70007-7","volume":"9","author":"D Conway","year":"2010","unstructured":"Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299\u2013308.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1882_CR11","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.clinthera.2013.07.330","volume":"35","author":"MM Bonafede","year":"2013","unstructured":"Bonafede MM, Johnson BH, Wenten M, Watson C. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Clin Ther. 2013;35(10):1501\u201312.","journal-title":"Clin Ther"},{"issue":"6","key":"1882_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.clinthera.2018.04.019","volume":"40","author":"J Visaria","year":"2018","unstructured":"Visaria J, Thomas N, Gu T, Singer J, Tan H. Understanding the Patient's journey in the diagnosis and treatment of multiple sclerosis in clinical practice. Clin Ther. 2018;40(6):926\u201339.","journal-title":"Clin Ther"},{"issue":"12","key":"1882_CR13","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1080\/03007995.2017.1380616","volume":"33","author":"FR Ernst","year":"2017","unstructured":"Ernst FR, Barr P, Elmor R, Wong SL. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon beta-1a or dimethyl fumarate: a real-world study. Curr Med Res Opin. 2017;33(12):2099\u2013106.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1882_CR14","doi-asserted-by":"crossref","first-page":"205521731769611","DOI":"10.1177\/2055217317696114","volume":"3","author":"J Nicholas","year":"2017","unstructured":"Nicholas J, Ko JJ, Park Y, Navaratnam P, Friedman HS, Ernst FR, et al. Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients. Multiple Scleros J- Exper Transl Clin. 2017;3(1):2055217317696114.","journal-title":"Multiple Scleros J- Exper Transl Clin"},{"key":"1882_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.msard.2018.11.004","volume":"27","author":"S Setayeshgar","year":"2019","unstructured":"Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, et al. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study. Mult Scler Relat Disord. 2019;27:364\u20139.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"1882_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3111\/13696998.2013.764309","volume":"16","author":"M Oleen-Burkey","year":"2013","unstructured":"Oleen-Burkey M, Cyhaniuk A, Swallow E. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. J Med Econ. 2013;16(3):397\u2013406.","journal-title":"J Med Econ"},{"issue":"8","key":"1882_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/1352458514556303","volume":"21","author":"J Widdifield","year":"2015","unstructured":"Widdifield J, Ivers NM, Young J, Green D, Jaakkimainen L, Butt DA, et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. Multiple Sclerosis (Houndmills, Basingstoke, England). 2015;21(8):1045\u201354.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"12","key":"1882_CR18","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/jamia\/ocy124","volume":"25","author":"G Hripcsak","year":"2018","unstructured":"Hripcsak G, Levine ME, Shang N, Ryan PB. Effect of vocabulary mapping for conditions on phenotype cohorts. J Am Med Inform Assoc: JAMIA. 2018;25(12):1618\u201325.","journal-title":"J Am Med Inform Assoc: JAMIA"},{"key":"1882_CR19","volume-title":"5-step briefing","author":"CT SNOMED","year":"2019","unstructured":"SNOMED CT, SNOMED CT. 5-step briefing; 2019. Available from: http:\/\/www.snomed.org\/snomed-ct\/five-step-briefing."},{"issue":"9","key":"1882_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","volume":"153","author":"PE Stang","year":"2010","unstructured":"Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600\u20136.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1882_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40120-017-0086-4","volume":"7","author":"MB Sintzel","year":"2018","unstructured":"Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Therapy. 2018;7(1):59\u201385.","journal-title":"Neurol Therapy"},{"issue":"17","key":"1882_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1212\/WNL.0000000000005399","volume":"90","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Giovannoni G, Trojano M. Complexity of MS management in the current treatment era. Neurology. 2018;90(17):761\u20132.","journal-title":"Neurology."},{"issue":"17","key":"1882_CR23","first-page":"777","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Rep Guideline Dev Dissemination, Implement Subcommittee Am Acad Neurol. 2018;90(17):777\u201388.","journal-title":"Rep Guideline Dev Dissemination, Implement Subcommittee Am Acad Neurol"},{"issue":"2","key":"1882_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 2018;24(2):96\u2013120.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"24","key":"1882_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1212\/WNL.0000000000005574","volume":"90","author":"JR Corboy","year":"2018","unstructured":"Corboy JR, Weinshenker BG, Wingerchuk DM. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology. 2018;90(24):1106\u201312.","journal-title":"Neurology."},{"issue":"4 Multiple Scle","key":"1882_CR26","first-page":"1046","volume":"19","author":"RA Marrie","year":"2013","unstructured":"Marrie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. Continuum (Minneapolis, Minn). 2013;19(4 Multiple Sclerosis):1046\u201357.","journal-title":"Continuum (Minneapolis, Minn)"},{"issue":"15","key":"1882_CR27","first-page":"1417","volume":"86","author":"LI Berrigan","year":"2016","unstructured":"Berrigan LI, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, et al. Health-related quality of life in multiple sclerosis. Direct indirect Effects Comorbidity. 2016;86(15):1417\u201324.","journal-title":"Direct indirect Effects Comorbidity"},{"issue":"1","key":"1882_CR28","doi-asserted-by":"publisher","DOI":"10.2196\/13018","volume":"6","author":"MS Cepeda","year":"2020","unstructured":"Cepeda MS, Reps J, Kern DM, Stang P. Medical conditions predictive of self-reported poor health: retrospective cohort study. JMIR Public Health Surveill. 2020;6(1):e13018.","journal-title":"JMIR Public Health Surveill"},{"issue":"14","key":"1882_CR29","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1212\/WNL.0000000000002543","volume":"86","author":"T Zhang","year":"2016","unstructured":"Zhang T, Tremlett H, Leung S, Zhu F, Kingwell E, Fisk JD, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016;86(14):1287\u201395.","journal-title":"Neurology."},{"issue":"3","key":"1882_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","volume":"15","author":"I Kister","year":"2013","unstructured":"Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, et al. Natural history of multiple sclerosis symptoms. Int J MS care. 2013;15(3):146\u201358.","journal-title":"Int J MS care"},{"issue":"5","key":"1882_CR31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","volume":"9","author":"N Koch-Henriksen","year":"2010","unstructured":"Koch-Henriksen N, S\u00f8rensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520\u201332.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1882_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40120-019-00156-5","volume":"8","author":"T Nazareth","year":"2019","unstructured":"Nazareth T, Datar M, Yu T-C. Treatment effectiveness for resolution of multiple sclerosis relapse in a US health plan population. Neurology Therapy. 2019;8(2):383\u201395.","journal-title":"Neurology Therapy"},{"issue":"9","key":"1882_CR33","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00415-015-7796-2","volume":"262","author":"SS Jick","year":"2015","unstructured":"Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol. 2015;262(9):2033\u201341.","journal-title":"J Neurol"},{"key":"1882_CR34","unstructured":"National Multiple Sclerosis Society. Types of MS 2020 [Last Accessed: May 18, 2020]. Available from: https:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01882-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T19:09:01Z","timestamp":1628622541000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01882-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1882"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01882-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-35509\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-35509\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-35509\/v2","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of the database was reviewed by the New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subjects research. Researchers did not have access to the raw administrative insurance claims data. The raw data was aggregated from insurance providers by the data provider which were then cleaned and de-identified, removing any personal identifying information. Access to the database containing the de-identified data for research purposes was granted by the data owner, Optum\u00a9, and is closed to public use.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Janssen Research & Development, LLC, which markets and develops treatments for depression, and are stockholders of Johnson & Johnson, Janssen\u2019s parent company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}